County Durham and Darlington NHS Foundation Trust (CDDFT) has confirmed that 20 women underwent mastectomies that, following a review of their care, may not have been necessary.
The admission forms part of a wider investigation into the trust’s breast care service. To date, the trust has reviewed 514 cases and concluded that 315 patients suffered some degree of harm, including 77 cases classified as involving significant harm. The review has also identified instances of delayed or missed cancer diagnoses, with some patients subsequently experiencing progression of their disease. The trust has confirmed that one patient is known to have died.
The review follows concerns raised about aspects of the breast unit’s practices, including higher-than-average mastectomy rates, the timing of some surgical interventions and arrangements under which certain breast cancer services were delivered through private providers linked to the trust’s former clinical lead for breast services, Mr Amir Bhatti.
Independent reviews have highlighted concerns regarding governance, clinical oversight and adherence to established treatment processes. A governance review also raised concerns that the outsourcing arrangements may have created financial incentives capable of influencing clinical decision-making, as NHS patients were referred to private clinics and surgical services linked to the consultant responsible for their care. The trust has acknowledged that a conflict of interest existed and was not managed appropriately. However, there has been no finding that treatment decisions were made for financial gain.
Review findings also identified concerns that some breast cancer cases may not have been considered through multidisciplinary team meetings in accordance with expected practice. Such meetings are intended to ensure that treatment options are discussed and reviewed by a range of specialists before significant decisions are made.
A number of former patients have since been informed that breast-conserving surgery may have been a treatment option that could have been considered in their cases, but that this was not discussed with them at the time. Many have spoken publicly about the lasting physical and psychological impact of their treatment.
The trust’s chief executive, Steve Russell, has issued an unreserved apology to affected patients and described the failings identified by the review as unacceptable. The trust is now considering whether to expand the scope of the review to include up to 10,000 breast cancer cases dating back to 2015.
Separately, Durham Police and the National Crime Agency are examining allegations arising from the matter to assess whether any criminal offences may have been committed. No conclusions have been reached.
Comment
While apologies and any future compensation arrangements are important, many patients are likely to regard accountability and transparency as the most pressing issues.
The review’s findings raise understandable questions about how concerns were able to persist over a prolonged period before being identified and addressed. Patients and their families will want a clear explanation of whether there were shortcomings in oversight, governance or clinical processes, and whether opportunities to identify problems at an earlier stage were missed.
Questions are also likely to be asked about whether arrangements identified by reviewers as creating potential conflicts of interest were subject to sufficient scrutiny and safeguards.
As calls for a public inquiry continue, many of those affected are seeking not only recognition of the harm they have suffered but a full and independent account of how these events occurred, together with assurances that any lessons identified will be acted upon to prevent similar concerns arising in the future.
Andrew is a clinical negligence specialist andrewkelly@benhoarebell.co.uk
